# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA1794382 | F | PUBCHEM_BIOASSAY: qHTS assay for small molecule antagonists of glucocorticoid receptor signaling. (Class of assay: confirmatory) | 332 | assay format | PubChem BioAssays | |||
2. | ALA1794399 | F | PUBCHEM_BIOASSAY: qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling. (Class of assay: confirmatory) | 412 | assay format | PubChem BioAssays | |||
3. | ALA1794415 | F | PUBCHEM_BIOASSAY: qHTS assay for small molecule agonists of farnesoid X receptor signaling. (Class of assay: confirmatory) | 270 | assay format | PubChem BioAssays | |||
4. | ALA2114853 | F | PubChem BioAssay. qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway. (Class of assay: confirmatory) | Homo sapiens | 180 | assay format | PubChem BioAssays | ||
5. | ALA2114895 | F | PubChem BioAssay. qHTS assay for small molecule activators of the p53 signaling pathway. (Class of assay: confirmatory) | Homo sapiens | 263 | assay format | PubChem BioAssays | ||
6. | ALA1909163 | B | DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) | Cavia porcellus | 871 | tissue-based format | DrugMatrix | ||
7. | ALA1909164 | B | DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) | 871 | cell membrane format | DrugMatrix | |||
8. | ALA1909165 | B | DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) | Oryctolagus cuniculus | 871 | tissue-based format | DrugMatrix | ||
9. | ALA1909166 | B | DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH) | 871 | cell membrane format | DrugMatrix | |||
10. | ALA1909167 | B | DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH) | 871 | cell membrane format | DrugMatrix | |||
11. | ALA1909168 | B | DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH) | 871 | cell membrane format | DrugMatrix | |||
12. | ALA1909169 | B | DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) | 871 | cell-based format | DrugMatrix | |||
13. | ALA1909170 | B | DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) | 871 | cell membrane format | DrugMatrix | |||
14. | ALA1909171 | B | DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) | 871 | cell membrane format | DrugMatrix | |||
15. | ALA1909172 | B | DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) | 871 | cell membrane format | DrugMatrix | |||
16. | ALA1909173 | B | DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) | 871 | cell membrane format | DrugMatrix | |||
17. | ALA1909174 | B | DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) | 871 | cell membrane format | DrugMatrix | |||
18. | ALA1909175 | B | DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY) | 871 | cell membrane format | DrugMatrix | |||
19. | ALA1909176 | B | DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY) | 871 | cell membrane format | DrugMatrix | |||
20. | ALA1909177 | B | DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine) | 871 | cell membrane format | DrugMatrix |